Market Insights report
Depressive disorders are common mental health disorders that can be diagnosed in patients of all age groups. Due to the rise in diagnosed depressive disorder cases that followed after many countries went into lockdown and enforced social distancing measures, the market saw a rise in worldwide antidepressant drug sales in 2021. Although it took some time for people to adapt to these impositions, they were able to adjust their lifestyle and routine.
The Depressive Disorders in the Mental Health market represent the market for antidepressant drug sales. Different types of antidepressants are usually prescribed for the treatment of mild to serious cases of depression, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), serotonin modulators, as well as tricyclic and tetracyclic antidepressants.
What's included?
This market report on Depressive disorders provides detailed insights into the Depressive disorders market from a global perspective. Besides all relevant market figures like worldwide revenues from 2016 to 2028, we have deep-dived into regional and country comparisons with a focus on Europe and the Americas.
The Depressive Disorders market was valued at 21.65 billion USD in 2022 and is expected to grow steadily between 2022 and 2028. The increasing prevalence of various types of depressive disorders and new product launches are driving the market. The largest markets include developed countries including the US, China, Japan, and Canada.
The major players include Novartis AG, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, Patheon Inc, Sandoz Inc. & Company among others.
Overview
Market numbers
We provide information on industries, companies, consumers, trends, countries, and politics, covering the latest and most important issues in a condensed format.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)